Combination therapy with lipid prodrug liposomes reshapes disease-associated neutrophils to promote the cancer-immunity cycle

Table 2 Artificial intelligence-assisted design of PEG-modified MLP liposomes incorporating varying phospholipid and cholesterol ratios. The characteristics include particle size, PDI, zeta potential, and encapsulation efficiency

Phospholipids: cholesterol (%)	Particle size (nm)	PDI	Zeta potential (mV)	Encapsulation efficiency (%)
HSPC: CH = 45: 50	296.70	0.14	− 12.45	68.26
HSPC: CH = 55: 40	239.96	0.14	− 11.21	68.63
HSPC: CH = 65: 30	239.71	0.14	− 8.84	69.29
HSPC: CH = 85: 10	240.54	0.14	− 7.78	73.35
HSPC: CH = 95: 00	238.22	0.15	− 7.89	73.50
POPC: CH = 45: 50	292.37	0.14	− 12.39	68.45
POPC: CH = 55: 40	244.64	0.14	− 11.56	68.40
POPC: CH = 65: 30	239.04	0.14	− 8.74	69.30
POPC: CH = 85: 10	240.01	0.14	− 7.72	73.49
POPC: CH = 95: 00	237.74	0.15	− 7.87	73.64
POPG: CH = 45: 50	303.54	0.14	− 15.96	63.66
POPG: CH = 55: 40	246.90	0.14	− 14.44	63.83
POPG: CH = 65: 30	247.01	0.14	− 12.32	64.32
POPG: CH = 85: 10	250.02	0.14	− 11.68	68.07
POPG: CH = 95: 00	247.70	0.15	− 12.13	67.81
DOPG: CH = 45: 50	302.98	0.15	− 15.46	63.83
DOPG: CH = 55: 40	254.21	0.14	− 14.52	63.75
DOPG: CH = 65: 30	247.63	0.14	− 11.82	64.39
DOPG: CH = 85: 10	250.73	0.14	− 10.63	68.01
DOPG: CH = 95: 00	248.38	0.15	− 11.06	67.75

HSPC, Hydrogenated Soy Phosphatidylcholine; POPC, 1-Palmitoyl-2-oleoylphosphatidylcholine; POPG, 1-Palmitoyl-2-oleoylphosphatidylglycerol; DOPG, Dioleoylphosphatidylglycerol

ISSN: 1477-3155